Hitoshi Zembutsu

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 6

Top Topics

Single Molecule

Tyrosine Kinase

Top Venues

Basic & clinical pharmacology & toxicology

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Niclas Björn, Ingrid Jakobsen Falk, Chihiro Udagawa, Eva Brandén, Hirsh Koyi, Rolf Lewensohn, Luigi De Petris, Hitoshi Zembutsu, Henrik Green
The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes. Basic & clinical pharmacology & toxicology 130 (4) (2022)
Chihiro Udagawa, Mari Hara Nakano, Teruhiko Yoshida, Yuichiro Ohe, Ken Kato, Taisei Mushiroda, Hitoshi Zembutsu
Association between genetic variants and the risk of nivolumab-induced immune-related adverse events. Pharmacogenomics 23 (16) (2022)
Chihiro Udagawa, Yasushi Sasaki, Yasuhiro Tanizawa, Hiroshi Suemizu, Yasuyuki Ohnishi, Yasukazu Nakamura, Takashi Tokino, Hitoshi Zembutsu
Whole-exome sequencing of 79 xenografts as a potential approach for the identification of genetic variants associated with sensitivity to cytotoxic anticancer drugs. PloS one 15 (9) (2020)
Chihiro Udagawa, Hitoshi Zembutsu
Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy. Cancer science 111 (10) (2020)
Satoshi Murahashi, Takashi Akiyoshi, Takeshi Sano, Yosuke Fukunaga, Tetsuo Noda, Masashi Ueno, Hitoshi Zembutsu
Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. British journal of cancer 123 (5) (2020)
Chihiro Udagawa, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takuji Okusaka, Hideki Ueno, Kenji Tamura, Yuichiro Ohe, Hitoshi Zembutsu
Whole genome sequencing to identify predictive markers for the risk of drug-induced interstitial lung disease. PloS one 14 (10) (2019)